Thiopurine methyltransferase and thiopurine metabolite testing in patients with inflammatory bowel disease who are taking thiopurine drugs

Pharmacogenomics

Volumn 10, Issue 7, 2009, Pages 1091-1099

  Sheffield, Leslie J ^a,b   Irving, Peter ^c   Gupta, Arun ^d   Byron, Keith ^e   Macrae, Finlay A ^d   Phillimore, Hazel ^b   Dronavalli, Mithilesh ^d,f   Rose, Rosemary ^c   George, Peter ^g   Walmsley, Trevor ^g   Dixon, Barbara ^h   Poole, Susan ^h   Dooley, Michael ^h,i   Sparrow, Miles ^c,h  

^a MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^b GenesFX Health Pty Ltd   (Australia)

^c BOX HILL HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e GRIBBLES PATHOLOGY   (Australia)

^f Data Clinic   (Australia)

^g CANTERBURY HEALTH LABORATORIES   (New Zealand)

^h ALFRED HEALTH   (Australia)

ⁱ MONASH UNIVERSITY   (Australia)

Author keywords

6 mercaptopurine; 6 methylmercaptopurine; 6 thioguanine nucleotides; Azathioprine; Dosage; Extensive metabolizer; Intermediate metabolizer; Thiopurine drugs; Thiopurine methyltransferase testing; TPMT

Indexed keywords

AZATHIOPRINE; DRUG METABOLITE; MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE;

CONFERENCE PAPER; CONTROLLED STUDY; DISEASE SEVERITY; DRUG METABOLISM; ENTERITIS; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PHARMACOGENOMICS; PHENOTYPE;

6-MERCAPTOPURINE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; GENETIC TESTING; HUMANS; INFLAMMATORY BOWEL DISEASES; METHYLTRANSFERASES; MIDDLE AGED; YOUNG ADULT;

EID: 70449482129     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.60     Document Type: Conference Paper

References (27)

1. Gearry R, Barclay M, Gardiner S, Zhang M: 6-thioguanine nucleotides and thiopurine methyltransferase activity: important factors determining response to treatment and incidence of adverse effects from azathioprine and 6-MP. N. Z. Med. J. 116(1178), U531 (2003). ■ Good guide to the use of these tests.
2. Gearry RB, Barclay ML: Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J. Gastroenterol. Hepatol. 20(8), 1149-1157 (2005).
3. McLeod HL, Siva C: The thiopurine S-methyltransferase gene locus - implications for clinical pharmacogenomics. Pharmacogenomics 3(1), 89-98 (2002). ■■ Clear explanation of the genetic types.
4. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C: Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst. Rev. (3), CD000545 (1998).
5. Gearry RB, Barclay ML, Roberts RL et al.: Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice. Intern. Med. J. 35(10), 580-585 (2005).
6. Woelderink A, Ibarreta D, Hopkins MM, Rodriguez-Cerezo E: The current clinical practice of pharmacogenetic testing in Europe: TPMT and HER2 as case studies. Pharmacogenomics J. 6(1), 3-7 (2006). ■ Europe also has a low uptake of pharmacogenomic tests. (Pubitemid 43118304)
7. Gardiner SJ, Begg EJ: Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol. Rev. 58(3), 521-590 (2006). ■■ Excellent review of the use of pharmacogenetics in the Australasian area.
8. Duley JA, Florin TH: Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides. Ther. Drug Monit. 27(5), 647-654 (2005).
9. Dooley M, Dixon B, Poole S, Chiang C, Whitlock A, Schneider H: Phenotyping for thiopurine therapy in clinical practice. J. Pharm. Pract. Res. 38, 188-190 (2008).
10. Corkindale D, Ward H, McKinnon R: Low adoption of pharmacogenetic testing: an exploration of the reasons in Australia. Personalized Medicine 4(2), 191-199 (2007). ■■ Good explanation of why doctors do not order pharmacogenomic tests. (Pubitemid 46845899)
11. Sandborn WJ: A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am. J. Gastroenterol. 91(3), 423-433 (1996).
12. Best WR: Predicting the Crohn's disease activity index from the Harvey-Bradshaw Index. Inflamm. Bowel Dis. 12(4), 304-310 (2006).
13. Walmsley RS, Ayres RC, Pounder RE, Allan RN: A simple clinical colitis activity index. Gut 43(1), 29-32 (1998).
14. Sies C, Florkowski C, George P et al.: Measurement of thiopurine methyltransferase activity guides dose-initiation and prevents toxicity from azathioprine. N. Z. Med. J. 118(1210), U1324 (2005).
15. StataCorp.: Statistical Software: Intercooled Release 9.1. Stata Corporation, TX, USA (2005).
16. Perneger TV: What's wrong with Bonferroni adjustments? BMJ 316(7139), 1236-1238 (1998).
17. Relling MV, Hancock ML, Rivera GK et al.: Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl Cancer Inst. 91(23), 2001-2008 (1999).
18. Gardiner SJ, Gearry RB, Begg EJ, Zhang M, Barclay ML: Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold. Clin. Gastroenterol. Hepatol. 6(6), 654-660 (2008).
19. Gisbert JP, Niño P, Rodrigo L, Cara C, Guijarro LG: Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Am. J. Gastroenterol. 101, 2679-2776 (2006). (Pubitemid 44902649)
20. Sanderson J, Ansari A, Marinaki T et al.: Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy ? Ann. Clin. Biochem. 41, 294-302 (2004). (Pubitemid 38954878)
21. Ansari A, Arenas M, Greenfield SM et al.: Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment. Pharmacol. Ther. 28(8), 973-983 (2008). ■■ Prospective study on the effect of therapeutic dose of thiopurine drugs on patients.
22. Cuffari C, Hunt S, Bayless TM: Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Aliment. Pharmacol. Ther. 14(8), 1009-1014 (2000). (Pubitemid 30618161)
23. Dubinsky MC, Yang H, Hassard PV et al.: 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 122(4), 904-915 (2002). (Pubitemid 34267273)
24. Dubinsky MC, Lamothe S, Yang HY et al.: Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118(4), 705-713 (2000). (Pubitemid 30171620)
25. Ganiere-Monteil C, Medard Y, Lejus C et al. Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age. Eur. J. Clin. Pharmacol. 60(2), 89-96 (2004). (Pubitemid 38626437)
26. Langley PG, Underhill J, Tredger JM, Norris S, McFarlane IG: Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. J. Hepatol. 37(4), 441-447 (2004).
27. Payne K, Newman WG, Gurwitz D, Ibaretta D, Phillips KA: TPMT testing in azathioprine:a 'cost effective use of healthcare resources'? Personalized Medicine 6(1), 103-113 (2009).